Mirabella Financial Services LLP purchased a new position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 36,455 shares of the company's stock, valued at approximately $778,000.
Several other institutional investors and hedge funds also recently made changes to their positions in KVUE. Norges Bank bought a new position in shares of Kenvue during the fourth quarter valued at $521,348,000. Franklin Resources Inc. increased its position in Kenvue by 61.5% during the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company's stock valued at $912,059,000 after purchasing an additional 16,269,721 shares during the period. Massachusetts Financial Services Co. MA raised its stake in Kenvue by 12.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company's stock worth $2,085,070,000 after buying an additional 10,682,003 shares during the last quarter. Boston Partners raised its position in shares of Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company's stock worth $503,145,000 after acquiring an additional 6,366,097 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Kenvue during the 4th quarter valued at about $98,926,000. Institutional investors and hedge funds own 97.64% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on KVUE shares. Royal Bank of Canada restated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Barclays lowered their price target on Kenvue from $23.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, April 14th. Evercore ISI started coverage on shares of Kenvue in a research report on Monday, March 24th. They issued an "in-line" rating and a $25.00 price objective for the company. UBS Group decreased their price target on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a research report on Friday, February 7th. Finally, Canaccord Genuity Group lifted their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Eight analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $24.42.
View Our Latest Report on KVUE
Kenvue Price Performance
Shares of Kenvue stock traded up $0.28 on Friday, reaching $23.03. The stock had a trading volume of 22,249,578 shares, compared to its average volume of 17,101,628. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market cap of $44.19 billion, a P/E ratio of 43.45, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. The business's 50 day moving average is $23.01 and its two-hundred day moving average is $22.42.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, research analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.
Kenvue Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be given a $0.205 dividend. The ex-dividend date is Wednesday, May 14th. This represents a $0.82 dividend on an annualized basis and a yield of 3.56%. Kenvue's payout ratio is 154.72%.
Kenvue Company Profile
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
See Also
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
